上海医药集团股份有限公司 证券代码：601607 证券简称：上海医药 公告编号：临2023-071 上海医药集团股份有限公司 关于高级管理人员辞任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"本公司"）董事会接到潘德青 先生的书面辞呈。因个人原因，潘德青先生辞去本公司副总裁及在本公司附属子 公司担任的全部职务，辞呈自送达本公司董事会之日起生效。该事项对本公司日 常经营无重大影响。 特此公告。 董事会 二零二三年九月二日 1 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached ¥132.59 billion, an increase of 18.70% compared to ¥111.71 billion in the same period last year[19]. - The net profit attributable to shareholders of the listed company was ¥2.61 billion, a decrease of 29.38% from ¥3.70 billion in the previous year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥2.20 billion, down 17.96% from ¥2.68 billion in the same period last year[19]. - The net cash flow from operating activities was ¥1.64 billion, a significant improvement from a negative cash flow of ¥556.18 million in the previous year[19]. - Total assets at the end of the reporting period amounted to ¥213.32 billion, reflecting a growth of 7.66% from ¥198.13 billion at the end of the previous year[19]. - The net assets attributable to shareholders of the listed company increased to ¥67.36 billion, a slight rise of 0.44% from ¥67.06 billion at the end of the previous year[19]. - Basic earnings per share decreased by 37.17% to CNY 0.71 compared to CNY 1.13 in the same period last year[21]. - Diluted earnings per share also decreased by 37.17% to CNY 0.71 from CNY 1.13 year-on-year[21]. - The weighted average return on equity fell by 2.54 percentage points to 3.82% from 6.36% in the previous year[21]. Revenue Segmentation - The pharmaceutical industrial segment generated revenue of RMB 14.699 billion, up 12.64% year-on-year, while the pharmaceutical commercial segment reported revenue of RMB 117.893 billion, a growth of 19.50%[38]. - The company's traditional Chinese medicine segment achieved industrial revenue of RMB 5.120 billion, a year-on-year increase of 21.64%[45]. - The sales of innovative drugs increased by about 24%, with 14 new imported products introduced during the reporting period[53]. Research and Development - Research and development investment reached RMB 1.218 billion, a year-on-year increase of 25.91%, with R&D expenses at RMB 1.026 billion, up 26.76%[41]. - The company has 64 new drug candidates in its pipeline, with 3 already submitted for pre-NDA or market application[41]. - The NDA application for I001, a new oral non-peptide renin inhibitor for hypertension, was accepted in June 2023, with significant market potential as the hypertension drug market in China was valued at RMB 26.75 billion in 2022[41]. - The company emphasizes R&D innovation, maintaining a leading position in R&D investment intensity within the industry[33]. Strategic Partnerships and Market Position - The company has established strategic partnerships with major domestic and international pharmaceutical manufacturers to enhance supply chain solutions[28]. - The company ranked 41st in the 2023 global pharmaceutical companies TOP50 and 3rd in the 2022 China pharmaceutical industry TOP100[27]. - The company is the second-largest pharmaceutical commercial enterprise in China, with a distribution network covering 25 provinces and municipalities[28]. Environmental Compliance and Sustainability - The company is committed to maintaining compliance with environmental regulations and improving its sustainability practices[130]. - The company has implemented online monitoring devices at wastewater discharge points to ensure compliance with environmental standards[135]. - The company has invested in multiple sets of air treatment facilities to manage emissions effectively[135]. - The company achieved 100% compliance in environmental monitoring from January to June 2023, with all monitored parameters meeting standards[149]. - The company plans to complete hardware facility rectifications by the end of 2023 to meet environmental requirements[147]. Corporate Governance and Compliance - The company strictly adhered to all applicable provisions of the Corporate Governance Code as per the Hong Kong Listing Rules during the reporting period[121]. - The board confirmed compliance with the Standard Code for Securities Transactions by Directors, ensuring all directors and supervisors fully adhered to the code during the reporting period[123]. - The audit committee reviewed and approved the accounting treatment methods adopted in the 2023 interim report[126]. Stock Options and Incentive Plans - The company has granted a total of 25,600,000 stock options, which were later adjusted to 23,258,120 due to changes in the number of participants[83]. - The stock options granted under the incentive plan amount to 25,025,520 shares, representing 1% of the company's total issued shares as of the report date[91]. - The exercise price for the stock options is set at RMB 18.41 per A-share, subject to adjustments for corporate actions[96]. - The incentive plan aims to align the interests of management with the long-term development of the company and prevent talent loss[85]. Legal and Regulatory Matters - The company has no significant pending litigation or arbitration to disclose during the reporting period[78]. - There are no significant lawsuits or arbitration matters affecting the company during the reporting period[169]. - The company has committed to not engaging in non-operational fund occupation by controlling shareholders and related parties[167]. Financial Transactions and Related Party Transactions - The total amount of related party transactions for the company was 22,884.92 million, representing 100% of the total transactions[171]. - The company reported a total of 3,093.25 million in related party purchases, which accounted for 100% of the related transactions[171]. - The company had a loan amount of 600,000.00 million with an interest rate range of 2.30%-5.00%[178].

公司-财-016-2023-V3 上海医药集团股份有限公司 担保管理制度 第一章 总则 第一条 为规范上海医药集团股份有限公司（以下简称"公司"）对外担保行为， 防范担保风险，根据《中华人民共和国物权法》、《中华人民共和国担保法》、《中华人民 共和国民法典》（以下简称"《民法典》"）、中国证券监督管理委员会及证券交易所等监 管机构对于上市公司对外担保的相关规定、以及公司《章程》等规定，结合公司实际情 况，特制定本制度。 第二条 本制度规定的担保是指根据《中华人民共和国担保法》规定的以其信用出 具对外担保，或以《中华人民共和国担保法》规定的财产对外抵押，或以《中华人民共 和国担保法》、公司《章程》等规定的动产或权利对外质押，向债权人或受益人承诺， 当债务人未按照合同约定偿付债务时由担保人履行偿付义务的行为。具体类型包括一般 保证、连带责任保证、抵押、质押、具有担保效力的共同借款合同、差额补足承诺、安 慰承诺、维好协议等支持性函件等各种形式的担保。 第三条 本制度规定的担保业务范围包括公司为控股公司、控股公司之间、控股公 司为公司的融资行为提供的保证担保、抵押担保和质押担保及为其他日常经营活动提供 的保证担保；公 ...

上海医药集团股份有限公司 独立董事的独立意见 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《上海证券交易所股票上市规则》等相关法律法规和《上海医 药集团股份有限公司章程》（以下简称"《公司章程》"）的相关规定，我们作为上海医药集 团股份有限公司（以下简称"公司"）的独立董事，基于独立客观判断，就上海上实集团财务 有限公司2023年半年度风险持续评估报告发表独立意见如下： 经审阅公司出具的《上海医药集团股份有限公司关于上海上实集团财务有限公司2023半年 度风险持续评估报告》，我们认为财务公司风险持续评估报告具备客观性和公正性，财务公司 具备开展业务的相关资质，未发现财务公司风险管理存在重大缺陷。公司与财务公司相关交易 均在签署的《金融服务框架协议》范围内进行，风险可控，未发现财务公司存在影响公司资金 安全及资金调动的情形，不存在损害公司和全体股东尤其是中小股东利益的情形。 董事会审议相关议案时关联董事依法回避表决，董事会审议和表决程序符合《公司法》、 《证券法》等有关法律、法规以及《公司章程》的规定。我们同意上海上实集团财务有限公司 2023半 ...

1、《2023 年半年度报告及摘要》 内容详见上海证券交易所网站 www.sse.com.cn。 表决结果：赞成 9 票，反对 0 票，弃权 0 票 2、《上海上实集团财务有限公司 2023 半年度风险持续评估报告》 证券代码：601607 证券简称：上海医药 公告编号：临2023-070 上海医药集团股份有限公司 第八届董事会第三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 上海医药集团股份有限公司（以下简称"本公司"或"上海医药"）第八届董事 会第三次会议（以下简称"本次会议"）于 2023 年 8 月 29 日在上海市太仓路 200 号上海医药大厦以现场方式召开。本次会议应到董事九名，实到董事九名，符合 《中华人民共和国公司法》和本公司章程关于董事会召开法定人数的规定。本次 会议由周军董事长主持，监事和部分高级管理人员列席本次会议。 二、董事会会议审议情况 本次会议审议并通过了以下议案： 上海医药集团股份有限公司 董事会 二零二三年八月三十日 内容详见上海证券交易所网站 w ...

上海医药集团股份有限公司 关于上海上实集团财务有限公司 2023 半年度风险持续评估报 告 根据《上海证券交易所上市公司自律监管指引第 5 号——交易与关联交易》的 要求，上海医药集团股份有限公司（以下简称"上海医药"或"我们"）通过查验 上海上实集团财务有限公司（以下简称"财务公司"）的《金融许可证》、《营业 执照》等证件资料，审阅其二〇二三年度中期财务报表，对经营资质、业务和风险 状况进行了解和评估。具体情况报告如下： 一、 企业基本情况及经营资质 上海上实集团财务有限公司由上海上实（集团）有限公司（股东一）、上海医 药集团股份有限公司（股东二）、上海上实资产经营有限公司（股东三）以及上海 实业东滩投资开发（集团）有限公司（股东四）合资成立。2014 年 9 月 1 日在中华 人民共和国上海市注册成立的有限责任公司。 财务公司于 2014 年 8 月 26 日取得中国银行业监督管理委员会上海监管局的沪 银监复、[2014]561 号开业批复，于 2014 年 9 月 1 日成立，注册资本人民币 10 亿 元整，己于 2014 年 5 月 19 日全部缴入。财务公司取得上海市黄浦区市场监督管理 局颁发的 0 ...

证券代码：601607 证券简称：上海医药 公告编号：临 2023-069 上海医药集团股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 8 月 25 日(周五)至 8 月 29 日(周二)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目进行提问。公 司将在说明会上对投资者普遍关注的问题进行回答。 上海医药集团股份有限公司（以下简称"公司"）将于 2023 年 8 月 29 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入 地了解公司 2023 年上半年经营成果、财务状况，公司计划于 2023 年 8 月 30 日下午 13:00-14:00 举行 2023 年半年度业绩说明会，就投资 者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年上 半年的经 ...

证券代码：601607 证券简称：上海医药 编号：临2023-068 上海医药集团股份有限公司 关于盐酸美金刚片获得批准生产的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"上海医药"或"公司"）下 属控股子公司上海上药中西制药有限公司（以下简称"上药中西"）的盐酸美金 刚片（以下简称"该药品"）收到国家药品监督管理局（以下简称"国家药监局"） 颁发的《药品注册证书》（证书编号：2023S01232、2023S01233），该药品获得 批准生产。 一、该药品基本情况 药物名称：盐酸美金刚片 剂型：片剂 规格：10mg、20mg 二、 该药品相关的信息 盐酸美金刚片主要用于治疗中重度至重度阿尔茨海默型痴呆。最早由 Merz 公司研发。2002 年，该产品在欧盟批准上市。2021 年 3 月，上药中西就该药品 向国家药监局提出注册上市申请，并获受理。 截至本公告日，中国境内该药品的主要生产厂家包括珠海联邦制药股份有 限公司中山分公司、湖南洞庭药业股份有限公司、广州白云山医药集团 ...

Financial Performance - In Q1 2023, the company achieved revenue of 66.226 billion RMB, a year-on-year increase of 16.39%[9] - The pharmaceutical manufacturing segment generated sales revenue of 7.801 billion RMB, up 12.60% year-on-year, with 60 key products contributing 4.604 billion RMB, a 13.84% increase[9] - The pharmaceutical commercial segment reported sales revenue of 58.425 billion RMB, reflecting a year-on-year growth of 16.92%[9] - The net profit attributable to shareholders was 1.518 billion RMB, representing a year-on-year increase of 21.31%, with the industrial business contributing 0.708 billion RMB and the commercial business contributing 0.861 billion RMB[9] - The company's revenue for the first quarter of 2023 was approximately ¥66.23 billion, representing a year-on-year increase of 16.39%[19] - The net profit attributable to shareholders was approximately ¥1.52 billion, reflecting a year-on-year growth of 21.31%[19] - Total operating revenue for Q1 2023 reached ¥66.23 billion, a 16.5% increase from ¥56.90 billion in Q1 2022[32] - Net profit for Q1 2023 was ¥1.95 billion, representing a 27.5% increase compared to ¥1.53 billion in Q1 2022[34] Research and Development - R&D investment reached 0.547 billion RMB, a 15.80% increase year-on-year, with R&D expenses at 0.541 billion RMB, up 20.82%[9] - The company has 64 new drug candidates in clinical research, including 52 innovative drugs and 12 improved new drugs[11] - The first self-developed new drug, I001, has completed Phase III clinical trials for hypertension, showing positive results[11] - The company has submitted a pre-NDA application for the new drug I008-A, targeting chronic immune disorders, which is expected to fill a clinical gap[12] - Research and development expenses for Q1 2023 were ¥540.69 million, an increase of 20.8% from ¥447.50 million in Q1 2022[33] - Research and development expenses increased to CNY 124,552,189.62 in Q1 2023 from CNY 106,026,867.46 in Q1 2022, reflecting a growth of about 17.5%[42] Market Expansion - The company is expanding its traditional Chinese medicine segment, leveraging historical brands and products with significant cultural heritage[13] - The company aims to enhance its market position in the Chinese medicine sector, supported by national policies promoting the industry[13] - The company has expanded its international presence by entering the Philippine market, with the approval of four specifications of Rosuvastatin Calcium Tablets[16] - The company plans to continue focusing on the Southeast Asian market to enhance its global commercial footprint[16] Assets and Liabilities - The total assets at the end of the reporting period were approximately ¥206.04 billion, an increase of 3.99% compared to the end of the previous year[19] - As of March 31, 2023, the total assets of the company amounted to RMB 206,035,799,280.43, an increase from RMB 198,134,901,498.95 as of December 31, 2022, reflecting a growth of approximately 4.8%[28] - The company's current assets totaled RMB 157,170,379,297.84, up from RMB 149,512,870,619.79, indicating an increase of about 5.5%[28] - Total liabilities as of Q1 2023 amounted to ¥126.15 billion, an increase from ¥120.13 billion in the previous year[30] - The total liabilities increased to CNY 24.60 billion from CNY 22.29 billion at the end of 2022[41] Cash Flow - The cash flow from operating activities was negative at approximately -¥2.62 billion, indicating increased cash outflows for purchases and services[19] - In Q1 2023, the company reported cash inflows from operating activities of approximately CNY 64.27 billion, an increase of 15.5% compared to CNY 55.91 billion in Q1 2022[35] - The net cash outflow from operating activities was CNY -2.62 billion, slightly worse than the CNY -2.49 billion reported in the same period last year[36] - The company generated CNY 9.56 billion from investment activities, a significant increase from CNY 180.58 million in Q1 2022[36] - The net cash outflow from investment activities was CNY -2.11 billion, compared to CNY -631.10 million in the previous year[36] - Cash inflows from financing activities totaled CNY 26.49 billion, down from CNY 34.75 billion in Q1 2022[36] - The net cash inflow from financing activities was CNY 4.31 billion, a decrease from CNY 17.59 billion in the same quarter last year[36] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 78,061[24] - The company reported a total of 3,698,499,159 shares issued, comprising 2,779,426,455 A-shares and 919,072,704 H-shares[26] Financial Ratios - The weighted average return on equity decreased to 2.24%, down by 0.26 percentage points from the previous year[19] - Total equity for Q1 2023 was ¥79.88 billion, up from ¥78.00 billion in Q1 2022[30] - The company's long-term borrowings increased to ¥8.60 billion in Q1 2023 from ¥6.26 billion in Q1 2022[30] - The company's financial expenses decreased to CNY 57,188,926.70 in Q1 2023 from CNY 80,460,137.77 in Q1 2022, a reduction of approximately 29%[42]

证券代码：601607 证券简称：上海医药 公告编号：临 2023-040 上海医药集团股份有限公司 关于召开 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： （网址：http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心音频直播结合网络互动 投资者可于 2023 年 04 月 23 日(星期天) 至 04 月 26 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 boardoffice@sphchina.com 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 上海医药集团股份有限公司（以下简称"公司"）将于 2023 年 4 月 26 日晚 发布《公司 2023 年第一季度报告》。为便于广大投资者更全面深入地了解公司 2023 年第一季度的经营成果和财务状况，公司计划于 2023 年 04 月 27 日下午 13:00-14:00 举行 2023 年第一季度业绩说明会，就投资者关 ...